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Introduction
Pseudomonas aeruginosa is one of the important caus-
es of hospital-acquired infections in intensive care unit 
(ICU) and considered as a major determinant of morbid-
ity and mortality in patients affected by cystic fibrosis 
(CF) [1-3]. 
Surveillance of nosocomial P. aeruginosa infections 
has revealed trends of increasing antimicrobial resist-
ance [4]. The emergence of transmissible P. aeruginosa 
strains at hospital and its spread to other P. aeruginosa-
negative patients raise concerns especially in ICU set-
tings, where the number of antibiotic agents with good 
activity is limited [5, 6]. Several studies describe the pa-
tient-to-patient transmission of this bacteria from cent-
ers related with CF patients [7, 8]. 
At our hospital, CF patients are cared in gastroenterol-
ogy ward and P. aeruginosa-positive and P. aerugino-
sa-negative patients are not separated from each other 
in this ward. In addition, these patients move to other 
wards especially ICU during their hospitalization. The 
aim of this study was to investigate epidemiology of an-
timicrobial resistance and clonal diversity among ran-
domly picked P. aeruginosa isolates of CF and the other 
hospitalized patients in ICU.
Material and methods 
Between January and December 2010, randomly picked 
P. aeruginosa isolates of infected patient in ICU and pa-
tients affected by CF were collected from the tertiary 
referral Children Medical Hospital in Tehran, Iran. The 
patients investigated in this study were all prone to P. 
aeruginosa infection. An infected patient was defined as 
a patient with clinical symptoms of infection, and from 
whom a clinical culture yielded a dominant growth of 
P.aeruginosa. Clinical information on P. aeruginosa pa-
tient isolates was collected from medical records. Infor-
mation included age, sex, length of hospital stay, history 
of transfer from another wards, clinical outcome and mi-
crobiological data. 
A number of CF patients had more than one isolates and 
some of them were isolated while they were transferred 
to the ICU. In addition several cultures were obtained 
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Summary
Introduction. Pseudomonas aeruginosa is one of the important 
causes of hospital-acquired infections in Intensive Care Unit 
(ICU) and considered as a major determinant of morbidity and 
mortality in patients affected by cystic fibrosis (CF). The aim of 
this study was to investigate clonal diversity among randomly 
picked P. aeruginosa isolates of CF and the other hospitalized 
patients in ICU.
Methods. Cultivation, identification, and antimicrobial suscep-
tibility testing of P. aeruginosa isolates were performed using 
standard techniques. The genetic similarity of the strains was 
investigated by amplification of the Enterobacterial Repetitive 
Intergenic Consensus-polymerase chain reaction (ERIC-PCR) 
sequence. 
Results and discussion. Among 49 isolates, sixteen were isolated 
from 11 patients affected by CF and 33 came from an epidemiologi-
cal investigation of 25 P. aeruginosa infected patients of ICU. Five 
clusters were generated for all isolates analyzed through ERIC-PCR 
genotyping. Two major clusters (B and C) were discovered in P. aer-
uginosa isolates of ICU and CF patients during the whole period of 
this study. Fifteen unique antibiogram patterns obtained from all iso-
lates and multi-resistant P. aeruginosa (MRPA) were identified in 23 
isolates (47%). MRPA isolates were detected in all clusters (except 
A) while pan-resistant isolates were recovered only in cluster C.
The high prevalence of related or identical isolates in CF and 
non-CF patients can be due to transmission of particular domi-
nant clones in ICU ward. Therefore, enhanced infection-control 
may become necessary to prevent further spread of clonal strains.
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Tab. I. patient details, origin and date of isolation, outcome and microbiological data of all the p. aeruginosa isolates.
Patient* isolates age 
(month)
gender ward type of 
specimen
lentgh 
of hospital 
stay(Day) 
time of 
isolation after 
hospitalization(Day)
outcome ERIC-PCR 
pattern
antibiogram 
pattern
1 a 11 m pICU Trachea tube 21 4 death d 12
2 a 12 m pICU Wound 30 6 discharge B 3
3 a 12 F pICU ear secretion 58 5 discharge C 15
4 a 7 m pICU Trachea tube 34 20 discharge e 11
5 a 2.5 F pICU Urine 29 2 discharge C 15
6 a 10 F pICU Urine 30 21 death C 15
7 a 6 F pICU Wound 11 10 death A 6
8 a 3 m pICU Urine 21 5 death B 7
9 a 11 F pICU Trachea tube 5 2 discharge B 8
10
a
3 F pICU Wound 22 12 death
B 7
b eye 22 B 4
11 a 7 F pICU Trachea tube 15 5 discharge B 4
12 a 120 m pICU Urine 13 2 discharge B 3
13 a 2 m pICU Trachea tube 5 3 death B 11
14
a 9 m pICU Trachea tube 39 4 discharge
B 4
b   Wound 17 B 3
15 a 108 F pICU Trachea tube 54 2 discharge B 2
16 a 24 m pICU Trachea tube 4 3 discharge A 7
17
a
4 F pICU
Blood
28
4
discharge
e 10
b Alveolar aspirate 14 A 3
c Sputum 8 A 3
d Alveolar aspirate 8 C 12
18
a
8 m pICU Trachea tube 18 2 discharge
C 2
b Urine 14 C 1
19
a
36
F
pICU Wound 40
3
discharge
B 7
b F 5 C 14
c F 20 C 12
20 a 4 m pICU Urine 25 1 discharge C 15
21 a 31 F pICU Urine 26 5 discharge B 3
22 a 36 m pICU Blood 58 1 dischrge C 15
23 a 120 m pICU Trachea tube 19 4 discharge B 3
24 a 24 m pICU pharynx 15 6 discharge C 14
25 a 3 F pICU Wound 51 3 death C 15
26 a 12 F pICU Wound 14 14 death C 15
27
a
192 F
gastroenterology Alveolar aspirate
56
4
death
B 6
b gastroenterology Sputum 40 B 7
c gastroenterology Sputum 46 B 6
28
a
72 m
pICU Trachea tube
12
2
death
B 5
b pICU Tracheal aspirate 7 B 13
c pICU Trachea tube 11 B 11
29 a 5 F pICU Sputum 10 1 dischage C 15
30 a 45 m gastroenterology Sputum 14 2 dischage B 8
31 a 120 m gastroenterology Sputum 12 2 death B 7
32 a 10 m pICU Wound 10 9 death C 15
33 a 5 F gastroenterology Urine 11 1 dischage B 9
34 a 7 m gastroenterology Urine 36 2 death C 15
35 a 72 m pICU Trachea tube 7 2 death
B 3
b gastroenterology Sputum 7 C 15
36 a 48 F gastroenterology Sputum 7 1 dischage B 10
*Isolates number of 26 to 36 isolated from CF patients. pICU: pediatric Intensive Care Unit
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from some patients as long as they stayed in the ICU. 
Cultivation, identification, and antimicrobial suscepti-
bility testing of P. aeruginosa isolates were performed 
using standard techniques [9].
Multi-resistant P. aeruginosa (MRPA) was defined as 
strains resistant to ≥ 3 of the following classes of antibi-
otics: antipseudomonal penicillins, antipseudomonal ox-
yimino-b-lactams, fluoroquinolones, aminoglycosides, 
and carbapenems [10].
The genetic similarity of the strains was investigated by 
amplification of the Enterobacterial Repetitive Intergen-
ic Consensus-polymerase chain reaction (ERIC-PCR).
sequence  [11]. Comparison of banding patterns was 
performed using Gelcompar II, version 6.5 (Applied 
Maths, Sint-Matens-latem, Belgium). Cluster analy-
sis was accomplished with the unweighted pair group 
method using average linkages (UPGMA). ERIC-PCR 
was performed for P. aeruginosa isolates and related-
ness among genetic clones was defined as 80% similar-
ity as belonging to one clone.
Results
During one year, 36 patients aged 3.5 to 192 month (av-
erage 33.4) were entered to this study. Table I illustrated 
the patient details, origin and date of isolation, outcome, 
ERIC-PCR and antibiogram pattern of all isolates. 
Among 49 isolates, sixteen were isolated from 11 pa-
tients affected by CF and 33 came from an epidemio-
logical investigation of 25 P. aeruginosa strains isolated 
from infected patients of ICU. 
P. aeruginosa isolates were recovered from trachea tube 
(26%), urine (18%), wound (16%), sputum (18%), al-
veolar aspirate (8%), blood (4%), tracheal aspirate (2%), 
ear secretion (2%), and eye (2%).
Average length of hospital stay in all patients was 24 
days. Of the 36 patients, 14 died during the study (case 
fatality rate, 39%); whereas half of them were from CF 
patients (case fatality rate, 64%). MRPA were identified 
in 23 isolates (47%) and consistently detected during the 
study period. Among all isolates, 11 considered as pan-
resistant isolates that 5 of them belonged to CF patients.
Five clusters were generated for all 
isolates analyzed through ERIC-PCR 
genotyping, which were designated 
alphabetically from A to D (Fig.  1). 
Cluster B and C comprised both ICU 
and CF isolates while cluster A, D and 
E had only isolates of ICU ward. Elev-
en isolates of cluster B were identical 
whereas cluster C comprised of only 3 
identical isolates. 
MRPA isolates were detected in all 
clusters (except A) while pan-resist-
ant isolates were recovered only in 
cluster C.
Cluster B and C was seen during the 
study period (4 seasons) (Fig. 2). Clus-
ter A was introduced during summer 
and remained present during the rest 
Fig. 1. dendrogram of genotype analysis derived from 49 p. aer-
uginosa isolates. The scale at the top represents the genetic dis-
tance between the isolates..
Fig. 2. distribution of different clusters during 2010.
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of the study. During the autumn, one patient appeared 
in cluster D and E. However, cluster D emerged in the 
third season, detection of this cluster during the winter 
did not occur. 
In our study, 15 unique antibiogram patterns obtained 
from all isolates (Tab. II). Most of the isolates were re-
sistant to antipseudomonal oxyimino-b-lactams. The 
highest percentage of susceptibility was seen in amino-
glycosides (71%) followed by piperacillin-tazobactam 
(67%), imipenem (63%), ciprofloxacin (59%), and 
meropenem (55%). Different antibiogram patterns were 
displayed in a number of isolates even with ≥ 95% simi-
larity.
Discussion
Our hospital is a tertiary referral center in which the ICU 
setting includes mixed patients such as CF patients and 
transmission of P. aeruginosa strains between CF and the 
other hospitalized patients in ICU is probable,Therefore 
genotyping of P. aeruginosa isolates seems to be essential 
to clarify our hospital epidemiology. The spread of infec-
tion from patients with CF is a definite risk in children’s 
wards especially in ICU [12, 13]. In this study, molecular 
typing suggests cross-transmission between CF and non-
CF patients. According to our results, infections were 
predominantly caused by strains with cluster B and C. 
presence of these patterns during the whole period of this 
study suggesting that these clones are adapted to our hos-
pital. Cluster B was identified in 25 strains (51% of all 
typed isolates) and highly appeared in the first 3 months 
of 2010 and circulated until end of the study.
Our analysis demonstrated that CF isolates are genotypi-
cally closely related to non-CF isolates. The two major 
clusters (B and C) in our study were discovered in both 
patient populations that suggest probable occurrence of 
cross-infection between these patients. 
Studies about P. aeruginosa cross-infection demonstrat-
ed controversy evidence of clonal spread in CF centers. 
Some studies have revealed convincing evidence of 
clonal spread at CF holiday camps or centers  [14-18]. 
Another study at the Vancouver CF Centre did not rep-
resent any evidence of significant cross-infection with 
P. aeruginosa [19]. 
Emergence of MDR expect to become more preva-
lent in many hospitals [20, 21]. There is no doubt that 
cross-transmission plays an important epidemiological 
role in MRPA isolates  [22, 23], so prevention of the 
acquisition of these isolates are essential due to lim-
ited therapeutic options and increased mortality  [24]. 
On the other hand, prevalence of strains with resistance 
to all antimicrobial agents is a major risk for hospital-
ized patients especially in CF patients because of rare 
P. aeruginosa eradication and subsequently occurrence 
of chronic infection [25, 26]. 
P. aeruginosa has capacity to develop resistance to es-
sentially antimicrobial agents  [27] and may require 
treatment with less commonly used antibacterial agents 
such as colistin [4]. 
Our results support other studies  [28] that mentioned 
aminoglycosides are clinically effective against P. aer-
uginosa isolates when administrated intravenously or by 
nebulization.
Finally, in our study the high prevalence of related or 
identical isolates in CF and non–CF patients can be due to 
transmission of particular dominant clones in ICU ward. 
This suggests cross-infection can occur between CF and 
non-CF patients. Therefore, enhanced infection-control 
including strict segregation policies, basic hygiene meas-
ures and continued microbiological surveillance may be-
come necessary to prevent further spread of clonal strains.
Tab. II. Antibiogram patterns of 49 p. aeruginosa isolates.
Pattern 
number
Isolates* CF FEP CP MEM CAZ PTZ IMP GM AM
1 18b S S S S S S S S S
2 15,18a S S S S r S S S S
3 2a,12,14b,17b,17c,21,23,35a r S S S S S S S S
4 10b,11,14a r S S S r S S S S
5 28a S S S r S S S r S
6 7,27a,27c r r S S S S S S S
7 8,10a,16,19a,27b,31 r r S S r S S S S
8 9,30 r r S r r S S S S
9 33 r r r r r S S S S
10 17a,36 r r S r r r S S S
11 2c,10b,28c r r r S r S r S S
12 1,17d,19c r r r r r r S S S
13 28b r r S S r S r r r
14 19b,24 r r r r r S r r r
15 2b,5,6,20,22,25,26,29,32,34,35b r r r r r r r r r
CF, Cephalothin; Fep, Cefepime; Cp, Ciprofloxacin; mem, meropenem; CAZ, Ceftazidime; pTZ, piperacillin-tazobactam; Imp, Imipenem; gm, gentamycin; 
Am, Amikacin 
* Isolate number of 26 to 36 belongs to CF patients
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